Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
This guide clarifies which investors benefit most from target date funds versus index funds, focusing on goals and involvement level.
26,623 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
NVIDIA stock is seeing summer momentum as AI infrastructure demand remains strong, but analysts flag key catalysts an...
Money isn’t just numbers—it's a team sport. Learn how mib: douglas heather boneparth approach investing as a couple, ...
Long-term investors face a simple question with bond ETFs: Should you chase broad market exposure or a focused corpor...
April data show the fed's favored inflation gauge rose modestly, keeping inflation well above the 2% target. Analysts...
New BEA data shows inflation pressing higher again, complicating the Fed's policy path. Investors weigh rate bets as ...
A concise look at a cash-first mindset in crypto markets. Learn how a disciplined cash reserve can shape when and how...
Public headlines rarely tell the whole story about the economy or your wallet. This article breaks down how political...
Is the Trump bull market about to end, or is this a chapter in a longer market cycle? This guide blends history, data...
May's inflation outlook from the Federal Reserve hints at bigger moves for markets. This guide explains what that mea...
Observers are seeing the stock market doing something rarely seen: broad gains across the DJIA, S&P 500, and Nasdaq a...
Berkshire Hathaway is sitting on an enormous cash reserve. Far from a weakness, that cash pile gives the company dry ...